Dysfunctional Hemoglobin
Dysfunctional Hemoglobin Pulse Co-ox
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
California
-
San Francisco, California, United States, 94118
- University of California San Francisco
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Subjects does not have significant medical problems
- Subject is willing to provide written informed consent
- Subject is between 18 and 45 years of age
Exclusion Criteria:
- Has a BMI greater than 31
- Has had any relevant injury at the sensor location site
- Has deformities or abnormalities that may prevent proper application of the device under test
- Has a known respiratory condition
- Is currently a smoker
- Has a known heart or cardiovascular condition
- Is currently pregnant
- Is female and actively trying to get pregnant
- Has a clotting disorder
- Is known to have a hemoglobinopathy such as (anemia, bilirubinemia, sickle-cell anemia, inherited or congenital methemoglobinemia)
- The subject has a COHb greater than 3% or MetHb greater than 2%
- Has taken blood thinners or medication with aspirin within the last 24 hours
- Has unacceptable collateral circulation from the ulnar artery
- Has donated more than 300 mL of blood within one month prior to start of study
- Is unwilling or unable to provide written informed consent to participate in the study
- Is unwilling or unable to comply with the study procedures
- Has another health condition which in the opinion of the principal investigator makes him/her unsuitable for testing
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Carboxyhemoglobin
Induced carboxyhemoglobin levels up tp 15 percent.
|
Comparison of pulse co-oximeters
Other Names:
|
|
Methemoglobin
Induced methemoglobin levels up to 15 percent.
|
Comparison of pulse co-oximeters
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Evaluate carboxyhemoglobin over the range of 0-15 percent as assessed by co-oximetry
Time Frame: 4 hours
|
4 hours
|
|
Evaluate methemoglobin over the range of 0-15 percent as assessed by co-oximetry
Time Frame: 4 hours
|
4 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Determine oxygen saturation accuracy in conditions of elevated carboxyhemoglobin
Time Frame: 4 hours
|
4 hours
|
|
Determine oxygen saturation accuracy in conditions of elevated methemoglobin
Time Frame: 4 hours
|
4 hours
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Phillip E Bickler, MD, PhD, University of San Francisco
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- QATP2338
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.